Stonebridge Financial Planning Group LLC Has $766,000 Holdings in Boston Scientific Co. (NYSE:BSX)

Stonebridge Financial Planning Group LLC boosted its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 31.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,574 shares of the medical equipment provider’s stock after acquiring an additional 2,068 shares during the quarter. Stonebridge Financial Planning Group LLC’s holdings in Boston Scientific were worth $766,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Highland Capital Management LLC purchased a new stake in shares of Boston Scientific during the 4th quarter worth about $4,887,000. Covenant Asset Management LLC purchased a new stake in shares of Boston Scientific during the 4th quarter worth about $3,405,000. Beacon Investment Advisory Services Inc. raised its stake in shares of Boston Scientific by 31.7% during the 4th quarter. Beacon Investment Advisory Services Inc. now owns 19,527 shares of the medical equipment provider’s stock worth $1,744,000 after purchasing an additional 4,702 shares in the last quarter. Oak Harvest Investment Services raised its stake in shares of Boston Scientific by 262.5% during the 4th quarter. Oak Harvest Investment Services now owns 40,776 shares of the medical equipment provider’s stock worth $3,642,000 after purchasing an additional 29,526 shares in the last quarter. Finally, Blue Trust Inc. raised its stake in shares of Boston Scientific by 43.7% during the 4th quarter. Blue Trust Inc. now owns 15,077 shares of the medical equipment provider’s stock worth $1,263,000 after purchasing an additional 4,585 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $104.42 on Friday. Boston Scientific Co. has a 1-year low of $71.88 and a 1-year high of $107.17. The firm has a market capitalization of $154.48 billion, a PE ratio of 83.54, a PEG ratio of 2.79 and a beta of 0.68. The business’s 50 day moving average is $99.87 and its 200-day moving average is $97.16. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The company had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same quarter last year, the firm earned $0.56 EPS. Boston Scientific’s revenue for the quarter was up 20.9% compared to the same quarter last year. Sell-side analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Citigroup raised their price target on Boston Scientific from $119.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday. Morgan Stanley raised their price objective on Boston Scientific from $120.00 to $125.00 and gave the company an “overweight” rating in a research note on Friday, May 16th. Evercore ISI raised their price objective on Boston Scientific from $110.00 to $112.00 and gave the company an “outperform” rating in a research note on Thursday, April 24th. Needham & Company LLC raised their price objective on Boston Scientific from $113.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, April 24th. Finally, Stifel Nicolaus raised their price objective on Boston Scientific from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. Twenty-three equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $114.87.

Insider Transactions at Boston Scientific

In related news, EVP Jeffrey B. Mirviss sold 4,675 shares of the business’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $104.25, for a total value of $487,368.75. Following the sale, the executive vice president now owns 28,454 shares of the company’s stock, valued at $2,966,329.50. The trade was a 14.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP John Bradley Sorenson sold 4,572 shares of the business’s stock in a transaction on Monday, May 5th. The shares were sold at an average price of $104.54, for a total value of $477,956.88. Following the completion of the sale, the executive vice president now directly owns 18,705 shares in the company, valued at approximately $1,955,420.70. This represents a 19.64% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 195,830 shares of company stock valued at $20,043,415. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.